Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

Carl&nbsp;E StafstromSection of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAObjective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Carl&nbsp;E Stafstrom
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/cfe937a5c07b45bca454856e4f55faf5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cfe937a5c07b45bca454856e4f55faf5
record_format	dspace
spelling	oai:doaj.org-article:cfe937a5c07b45bca454856e4f55faf52021-12-02T00:25:13ZUpdate on the management of Lennox-Gastaut syndrome with a focus on rufinamide1176-63281178-2021https://doaj.org/article/cfe937a5c07b45bca454856e4f55faf52009-10-01T00:00:00Zhttp://www.dovepress.com/update-on-the-management-of-lennox-gastaut-syndrome-with-a-focus-on-ru-a3664https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Carl&nbsp;E StafstromSection of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAObjective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome.Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication.Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects.Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication&rsquo;s clinical response profile and potential for adverse effects.Keywords: pediatric, epilepsy, epileptic encephalopathy, Lennox-Gastaut syndrome, rufinamide Carl&nbsp;E StafstromDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 547-551 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Carl&nbsp;E Stafstrom Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
description	Carl&nbsp;E StafstromSection of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAObjective: This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome.Methods: A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication.Results: The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects.Conclusions: Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication&rsquo;s clinical response profile and potential for adverse effects.Keywords: pediatric, epilepsy, epileptic encephalopathy, Lennox-Gastaut syndrome, rufinamide
format	article
author	Carl&nbsp;E Stafstrom
author_facet	Carl&nbsp;E Stafstrom
author_sort	Carl&nbsp;E Stafstrom
title	Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
title_short	Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
title_full	Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
title_fullStr	Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
title_full_unstemmed	Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
title_sort	update on the management of lennox-gastaut syndrome with a focus on rufinamide
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/cfe937a5c07b45bca454856e4f55faf5
work_keys_str_mv	AT carlampnbspestafstrom updateonthemanagementoflennoxgastautsyndromewithafocusonrufinamide
_version_	1718403769042993152

Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

Ejemplares similares